Increasing Base Of Target Population Is Driving Forces Behind Growth Of Microbiome Therapeutics Market
San Francisco, 27 Dec 2018 — “Microbiome Therapeutics Market By Type (Fecal Microbial Transplant [FMT], Drugs) By Application (C. difficile, Crohn’s Disease, Inflammatory Bowel Disease [IBD], Diabetes), By Region, And Segment Forecasts, [2018–2025]”, According to a report published by Grand View Research, Inc.; the global microbiome therapeutics market is projected to reach a valuation of around USD 433.5 million by 2025. Increasing spending on research related to the development of biological drugs and governments support can impel market growth over the forecast period (2018 to 2025). Furthermore, strong drug pipeline and growing collaborations among pharmaceutical companies to for drug development can bode well for market expansion in near future.
Factors such as aging, unhealthy lifestyle, and frequent and long-term use of antibiotics can reduce the number of beneficial microorganisms in the human body. Many researchers state that change in the number of microorganism such as actinobacteria, bacteroidetes, and firmicute responsible can lead to diabetes, neurological disorders, gastrointestinal complaints, and arthritis among other health conditions.
Access Full Insights On Microbiome Therapeutics Market: www.grandviewresearch.com/industry-analysis/microbiome-therapeutics-market
High occurrence of diseases owing to dysbiosis of microbiota in the gut can drive growth of the market for microbiome therapeutics. Gut microbiome is linked with healthiness of an individual, and low level of gut microbiota can lead to fatal infectious diseases and organisms like ulcerative colitis and Clostridium difficile (C. difficile). People undergoing antibiotic treatment are at high risk of C. difficile infection during the treatment or the following moths of the treatment.
The worldwide microbiome therapeutics market can be segmented on the basis of type, application, and region. As per type, the market can be bifurcated into Fecal Microbial Therapy (FMT) and microbiome drugs. The FMT segment led the market in 2015. Introduction of FMT capsules coupled with growth in research activities carried out to discover more therapeutic applications of FMT are expected to drive the segment growth. The microbiome drugs segment is likely to display remunerative growth during the forecast period. This can be ascribed to existence of strong product pipeline with more than 27% drugs in phase 2. SER-109, NM504, SGM-1019, and RP-G28 are expected to be some of the high revenue generating drugs.
Based on application, the market for microbiome therapeutics can be categorized into diabetes, Crohn’s disease, C. difficile, Inflammatory Bowel Disease (IBD), and others. The C. difficile led with over 40.0% market share in 2015 on account of approval of FMT in the treatment of C. The Crohn’s disease segment is projected to display rapid growth in the forthcoming years. Over 20% of pipeline drugs are intended for the treatment of Crohn’s disease. Other applications such as lactose intolerance treatment are likely to register promising growth during the study period. Commercialization of drugs including RP-G28 after 2019 is anticipated to bode well for the growth.
Geographically, the market can be divided into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa. North America led the market in 2015 on account of well-established healthcare infrastructure, high research activities, and presence of pharmaceutical companies. In addition, increasing healthcare spending and presence of health-conscious population are considered as crucial factors responsible for regional growth. Europe was the second-largest region after North America with difference of just 9.0% in the market share.
Asia Pacific, on the other hand, is likely to expand a CAGR of over 49% during the forecast period. This growth can be attributed to increasing biological research efforts in national institutes, rising awareness about novel therapeutics among physicians, and improving economic conditions. In addition, growing practice of FMT in emerging countries such as China and India are likely to spur the regional growth.
Some of the leading companies operating in the microbiome therapeutics market include Second Genome, Inc.; Rebiotix, Inc.; ENTEROME Bioscience; MicroBiome Therapeutics; and Ritter Pharmaceuticals. Companies are investing heavily in new product development and strategic initiatives like venture capital investments. This is likely to create growth avenues in developed and emerging countries.
Market participants are also putting efforts to discover drug molecules with more than one application to gain higher market share. For instance, RP-G28 by Ritter Pharmaceutical is under clinical trials for lactose intolerance. It is also examined for Irritable Bowel Syndrome (IBS), ulcerative colitis, and Crohn’s disease.
Access More Reports Of The Same Category: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the microbiome therapeutics market on the basis of type and application:
Type Outlook (Market Revenue in USD Million, 2014–2025)
- Microbiome Drugs
Application Outlook (Market Revenue in USD Million, 2014–2025)
- C. difficile
- Crohn’s disease
- Inflammatory Bowel Disease
Regional Outlook (Market Revenue in USD Million, 2014–2025)
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
Browse Press Release of this Report: www.grandviewresearch.com/press-release/global-microbiome-therapeutics-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com